Bitopic ligands represent a powerful strategy to modulate G protein-coupled receptors by simultaneously engaging orthosteric and allosteric binding sites. In this study, we designed and synthesized two series of dequalinium-based hybrid ligands targeting muscarinic acetylcholine receptors (mAChRs), in which a dequalinium fragment was linked through polymethylene spacers of variable length either to the orthosteric superagonist iperoxo (Deq-X-Iper, 5a-c) or to a molecular portion of the allosteric inverse agonist W84 (Deq-X-W84, 6a-c). Equilibrium and kinetic binding studies at human mAChR subtypes (hM1-hM5) revealed good to high affinity for all compounds and a consistent bitopic mode of action, supported by a spacer-length-dependent enhancement of both orthosteric and allosteric interactions. Functional assays showed that Deq-X-W84 derivatives act as unselective muscarinic antagonists, whereas Deq-X-Iper ligands behave as agonists. Notably, the latter displayed probe-dependent negative allosteric modulation of acetylcholine-induced ERK1/2 phosphorylation at the hM4 receptor, revealing an unexpected functional profile. Docking and molecular dynamics simulations provided a structural rationale for these findings, highlighting stable bitopic binding poses and linker-dependent optimization of receptor contacts. Overall, these results demonstrate that dequalinium-based bitopic ligands can encode distinct functional outcomes at muscarinic receptors, offering new insights into the design of ligands with tailored signaling profiles.

Dequalinium-based bitopic ligands uncover distinct pharmacological modulation of muscarinic receptors / R. Ferrisi, S. Vittorio, S. Morando, C. Giorgio, N. Brivio, E. Cortese, A. Colleoni, C. Papotto, C. Matera, M.D. Amici, E. Barocelli, G. Vistoli, R. Matucci, C. Dallanoce. - In: BIOCHEMICAL PHARMACOLOGY. - ISSN 0006-2952. - 250:Pt 2(2026 Aug), pp. 118019.1-118019.14. [10.1016/j.bcp.2026.118019]

Dequalinium-based bitopic ligands uncover distinct pharmacological modulation of muscarinic receptors

R. Ferrisi
Primo
;
S. Vittorio
Secondo
;
A. Colleoni;C. Papotto;C. Matera;M.D. Amici;G. Vistoli;C. Dallanoce
Ultimo
2026

Abstract

Bitopic ligands represent a powerful strategy to modulate G protein-coupled receptors by simultaneously engaging orthosteric and allosteric binding sites. In this study, we designed and synthesized two series of dequalinium-based hybrid ligands targeting muscarinic acetylcholine receptors (mAChRs), in which a dequalinium fragment was linked through polymethylene spacers of variable length either to the orthosteric superagonist iperoxo (Deq-X-Iper, 5a-c) or to a molecular portion of the allosteric inverse agonist W84 (Deq-X-W84, 6a-c). Equilibrium and kinetic binding studies at human mAChR subtypes (hM1-hM5) revealed good to high affinity for all compounds and a consistent bitopic mode of action, supported by a spacer-length-dependent enhancement of both orthosteric and allosteric interactions. Functional assays showed that Deq-X-W84 derivatives act as unselective muscarinic antagonists, whereas Deq-X-Iper ligands behave as agonists. Notably, the latter displayed probe-dependent negative allosteric modulation of acetylcholine-induced ERK1/2 phosphorylation at the hM4 receptor, revealing an unexpected functional profile. Docking and molecular dynamics simulations provided a structural rationale for these findings, highlighting stable bitopic binding poses and linker-dependent optimization of receptor contacts. Overall, these results demonstrate that dequalinium-based bitopic ligands can encode distinct functional outcomes at muscarinic receptors, offering new insights into the design of ligands with tailored signaling profiles.
Bitopic ligands; Dequalinium; Iperoxo; Molecular modeling; Muscarinic acetylcholine receptors; Probe-dependent modulation; W84;
Settore CHEM-07/A - Chimica farmaceutica
ago-2026
28-apr-2026
https://authors.elsevier.com/a/1n1ep1RcujR17
Article (author)
File in questo prodotto:
File Dimensione Formato  
Biochemical Pharmacology 250 (2026) 118019.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Licenza: Nessuna licenza
Dimensione 8.58 MB
Formato Adobe PDF
8.58 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Journal Pre-proofs DOI 10.1016j.bcp.2026.118019.pdf

embargo fino al 01/09/2027

Descrizione: Pre-proofs
Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Licenza: Creative commons
Dimensione 3.56 MB
Formato Adobe PDF
3.56 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1241482
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
  • OpenAlex ND
social impact